Jeffrey L. Ives - Aug 17, 2023 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Director
Signature
/s/ Derek Meisner, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Aug 17, 2023
Transactions value $
-$240,814
Form type
4
Date filed
8/18/2023, 06:31 PM
Previous filing
Jun 7, 2023
Next filing
Jun 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Options Exercise $28.2K +39.1K $0.72* 39.1K Aug 17, 2023 Direct
transaction ABOS Common Stock Sale -$254K -39.1K -100% $6.48 0 Aug 17, 2023 Direct F1
transaction ABOS Common Stock Options Exercise $3.33K +2.8K $1.19* 2.8K Aug 17, 2023 Direct
transaction ABOS Common Stock Sale -$18.6K -2.8K -100% $6.66 0 Aug 17, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Stock Option (right to buy) Options Exercise $0 -39.1K -100% $0.00* 0 Aug 17, 2023 Common Stock 39.1K $0.72 Direct F2
transaction ABOS Stock Option (right to buy) Options Exercise $0 -2.8K -100% $0.00* 0 Aug 17, 2023 Common Stock 2.8K $1.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on May 17, 2023.
F2 The option is fully vested.